

CD3

Centre for Drug Design and Discovery

"The investment fund for innovative small

molecule "academic" drug discovery"

16 June 2010 UCL - Sopartec



THE CENTRE FOR DRUG DESIGN AND DISCOVERY

IS A GAP FUNDING AND TECHNOLOGY TRANSFER PLATFORM

FOR EARLY PHASE INNOVATIVE SMALL MOLECULE DRUG DISCOVERY AND TARGET VALIDATION

ESTABLISHED END 2006 BY K.U.LEUVEN R&D

IN COLLABORATION WITH EXTERNAL PARTNERS


European Investment Fund – EIF Universities / Research Institutes Spin-off companies CROs





Starting point: significant gap and need in technology transfer !





TRANSFER & TRANSLATION OF THIS EXCELLENT AND INNOVATIVE RESEARCH TO POTENTIAL TREATMENTS IS OFTEN LACKING


- Many times too early to be taken up by pharma/biotech industry
- · Lack of seed funding in the early stages of drug development
- Lack of drug discovery and development capacity at academic institutions
 - high-throughput screening
 - obtaining proof-of-principle
 - medicinal chemistry

- target validation
- ADMET



EUROPEAN INVESTMENT FUND

CD3 closes the gap, stimulates innovation and creates value in the drug discovery process



Drug Discovery process





CD3 = Investment fund with professional small molecule drug discovery support



GOAL	"Si	timulating and optimizing the transformation of innovative biomedical research into clinical small molecule drugs and create cures for diseases with a high need for treatments"				
STRATEGY	1.	Supplement (academic) biomedical research with all expertise lacking for professional small molecule drug discovery				
	2.	Fully apply the biomedical expertise and capacity present at the universities, research institutes or spin-offs – they perform biology				
	3.	Focus on innovative specific targets/approaches/chemical classes which are not (or minimally) investigated in pharma-industry				
	4.	Develop until "lead" compound class with broad IP-protection in ~2y, then license to industry or create spin-off				
Centralised facility and team for professional medicinal chemistry, ADME-Tox and drug discovery coordination with own funds in collaboration with academic experts						
TARGET Universi		iversities, spin-offs and research institutes				
BENEFIT Everybody = universities, industry, society, investors, scientists, e						
KATHOLIEKE UNIVERSITEIT						



INVESTMENT

FUND

CD3 = TT platform with professional small molecule drug discovery support and own funds



CD3 will complement an innovative biomedical research project with everything missing for professional drug discovery:

- support in "target identification and validation stage"
- high value compounds
 - such as compound libraries: 35.000 to 50.000 "high value" compounds
 - focussed libraries (i.e. targeting kinases, GPCRs, PPIs, etc.)
- high throughput screening (HTS) facilitation and performance
- in silico drug design, modelling and screening
- pharma compliant medicinal chemistry expertise
- chemical synthesis in hit to lead projects
- preliminary ADME-Tox (in vitro tox, metabolism, pharmaco-kinetics, etc)
- project coordination and follow-up
- IP support specific for the small molecule drug field


Lead compounds class and target validation with IP in 2 years





CD3 established multiple collaborations & contacts and has strategic partnerships = big network





KULeuven, VIB, UCL, UGent, companies, AMC, UGroningen, etc. Potentially to J&J, GSK, Pfizer, Vertex, Gilead Sciences, Roche, Astra-Zeneca, BI, Novartis, BMS, Abbott, Sanofi-Aventis, Merck, etc.




EUROPEAN INVESTMENT FUND

CD3 uses strict project selection criteria & tight governance



Four major types of projects (+ combinations)



Industrially managed with clear procedures

Selection of projects is based on specific and strict criteria

target, assay, research group, indication, innovation, market, etc.

• IP follow-up, business development, Scientific Advisory Board, Investment Committee, Consultants



CD3 Investment Committee & Scientific Advisory Board are fully operational and attracted top professionals



INVESTMENT COMMITTEE (IC)

- KUL: 2 members
- EIF: 2 members

- 1. Paul Van Dun
- 2. Bernard Majoie
- 1. Henri-François Boedt / Felicitas Riedl
- 2. Sue Foden

SCIENTIFIC ADVISORY BOARD

- 1. Dr. Brunner
- 2. Prof. E. De Clercq
- 3. Dr. C. Greengras
- 4. Dr. C. Lipinski








3 years operational

- Fully equiped (~pharma industry) possibility for 16 full time chemists
- Access to a high level professional team
 - 14 medicinal chemists 1 biologist multiple returned from pharma industry
- IC and SAB fully operational
- Pipeline is filling: multiple proposed projects under evaluation
 - ~multiple Screening projects in progress
 - 10 Development Projects approved





Multiple project proposals have been received Status end 2009






Multiple project proposals have been received Status end 2009



89 project proposals evaluated







CD3's Development projects already resulted in highly innovative results



	Screening SBDD	Hit compound validation	Hit-to-lead	In vivo POC
1. <u>Alzheimer's disease</u> <i>Tau aggregation induced tox.inhibitors</i>				
2. <u>Human Immunodeficiency virus</u> LEDGF-integrase inhibitors				
3. <u>Auto-immune dis. / transplant rej.</u> <i>B inhibitors</i>				
4. <u>Overactive bladder – cancer</u> <i>C inhibitors</i>				
5. <u>Human rhino virus (asthma, COPD)</u> phenotypic				
6. <u>Dengue virus</u> phenotypic				
7. <u>Cancer</u> MDM2-p53 inhibitors				
8. <u>Arthritis</u> BMP modulators				
				IN ENT 13

June 2010 – selection of CD3's ongoing Screening **Projects**



		Assay Active Hit Hit validation				
4 Influence states		Valid	Identif.	Confirm.	Sec. Assays	Analogs Chemi
1. Influenza virus	a la cara de varia				•	
0 Concer	phenotypic		1			
2. Cancer	MOTI inhihitana	Presente	ed as Deve	elopment Pr	oject proposal	
0. Oh en dre seleine si	MCT1 inhibitors	:		:		
3. Chondrocalcinosis						
	x inhibitors			:	:	
4. Antibacterials						
	y inhibitors			:	:	
5. Antibacterials						
	z inhibitors	:		:		
6. Chikungunya virus						
	phenotypic	:		:	: :	
7. FCV / FMDV						
0 F aillean and f an a all	phenotypic			:		
8. Epilepsy – "mood"	disorders					
9. Cancer						
	w inhibitors	:		:		
10. HIV						
	v inhib	:				
11. Biofilm formation						
	phenotypic				=	<u> </u>
KATHOLIEKE UNIVERSITEIT						EUROPEAN INVESTMENT EUND 14

FUND



First in-class inhibitors of the LEDGF/p75-integrase interaction and HIV replication

Publication May 16th Nature Chemical Biology






CD3: Licensing to Pharma & Biotech companies



- 2003 LEDGF/p75 is a co-factor of HIV replication (Cherepanov *et al.,* J. Biol. Chem.)
- 2006 LEDGF/p75 tethers IN to the chromatin (Llano *et al.*, Science)
- 2006 Overexpression of the LEDGF/p75 integrase binding domain (IBD) inhibits HIV replication (De Rijck *et al.*, J. Virol.)
- 2007 Start investment in drug discovery project in n collaboration with Prof. Z. Debyser (KULeuven)
- 2009 New anti-HIV drugs inhibiting LEDGF-integrase interaction identified
- 2009 Multiple patent applications filed Business Development with Big Pharma initiated
- 2010 Highly active anti-HIV drugs identified ~existing drugs kills all resistant viruses
- 2010 Publication Nature Chemical Biology
- 2010 Exclusive license to be established with Big Pharma







THANK YOU FOR YOUR ATTENTION





17